The LentiPeak™ Platform
Our proprietary lentiviral vector (LVV) platform is customized to meet your specific development needs.
We offer our partners a suspension-based, scalable lentiviral vector production platform.
Streamlined Tech Transfer between PD and cGMP manufacturing with aligned unit operations, equipment, bill of materials and analytics
Available cGMP capacity without waiting time
Parallel development with cell processing activities for ex-vivo programs
Efficient supply chain management & risk mitigation
Comprehensive regulatory support package
Integrated analytical support with panels of established testing methods in-house
Process utilizes a 4-plasmid 3rd gen LV system and a HEK 293 suspension cell line
Pre-established cGMP documentation and trained technical team
Proven platform performance with various CAR and TCR constructs at multiple production scales
LentiPeak™ Platform: Process Overview
- HEK293 cell line
- Suspension based, serum free
- Transient Transfection
- 3rd Generation LV plasmid system
- Accommadates a large range of GOI sizes
- Supporting analytics
- High functional titers
- 1.00E+08 to 1.00+09 TU/mL
Learn More About our Work in Lentiviral Vector Development
BioPharm International publication on the strategies and tactics for designing an ideal lentiviral vector platform
Poster on our lentiviral vector platform presented at the fall 2022 BioProcess International Conference
“De-risking lentiviral vector production using a robust, scalable, suspension-based platform” webinar
Where the Innovation Happens
BaseCamp is the innovation engine where technology, expertise, operations, processes, and GMP manufacturing come together to overcome industry challenges and accelerate the development of advanced therapies.
Cell Platform Manufacturing Processes
- Cell therapy process tools and equipment
- Platform processes for CAR-T and TCR-T
- Modular unit operations to accommodate multiple cell types
How can we support your project goals?
// Connect with us